Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status

Cancer Letters

Volumn 298, Issue 2, 2010, Pages 231-237

  Tian, Junqiang ^a   Peehl, Donna M ^a   Zheng, Wengwei ^b   Knox, Susan J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Glutathione; HDp44mT; Radiosensitization; Redox

Indexed keywords

ANTINEOPLASTIC AGENT; DI 2 PYRIDYL KETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; IRON CHELATING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HUMAN CELL; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIZATION;

ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; EPITHELIAL CELLS; GLUTATHIONE; HUMANS; INTRACELLULAR SPACE; IRON; IRON CHELATING AGENTS; MALE; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; OXYGEN; PROSTATE; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; THIOSEMICARBAZONES;

EID: 77957943591     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.07.010     Document Type: Article

References (20)

1. Richardson D.R., Kalinowski D.S., Lau S., Jansson P.J., Lovejoy D.B. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim. Biophys. Acta 2008.
2. Chaston T.B., Lovejoy D.B., Watts R.N., Richardson D.R. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin. Cancer Res. 2003, 9:402-414.
3. Samuni A.M., Krishna M.C., DeGraff W., Russo A., Planalp R.P., Brechbiel M.W., Mitchell J.B. Mechanisms underlying the cytotoxic effects of tachpyr - a novel metal chelator. Biochim. Biophys. Acta 2002, 1571:211-218.
4. Bernhardt P.V., Caldwell L.M., Chaston T.B., Chin P., Richardson D.R. Cytotoxic iron chelators: characterization of the structure, solution chemistry and redox activity of ligands and iron complexes of the di-2-pyridyl ketone isonicotinoyl hydrazone (HPKIH) analogues. J. Biol. Inorg. Chem. 2003, 8:866-880.
5. Becker E.M., Lovejoy D.B., Greer J.M., Watts R., Richardson D.R. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Brit. J. Pharmacol. 2003, 138:819-830.
6. Singh S., Khodr H., Taylor M.I., Hider R.C. Therapeutic iron chelators and their potential side-effects. Biochem. Soc. Symp. 1995, 61:127-137.
7. Graf E., Mahoney J.R., Bryant R.G., Eaton J.W. Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J. Biol. Chem. 1984, 259:3620-3624.
8. Chaston T.B., Richardson D.R. Iron chelators for the treatment of iron overload disease: relationship between structure. Redox activity, and toxicity. Am. J. Hematol. 2003, 73:200-210.
9. Yuan J., Lovejoy D.B., Richardson D.R. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 2004, 104:1450-1458.
10. Richardson D.R., Sharpe P.C., Lovejoy D.B., Senaratne D., Kalinowski D.S., Islam M., Bernhardt P.V. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J. Med. Chem. 2006, 49:6510-6521.
11. Whitnall M., Howard J., Ponka P., Richardson D.R. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad. Sci. USA 2006, 103:14901-14906.
12. Rosenberg A., Knox S. Radiation sensitization with redox modulators: a promising approach. Int. J. Radiat. Oncol. Biol. Phys. 2006, 64:343-354.
13. Peehl D.M. Primary cell cultures as models of prostate cancer development. Endocr. Relat. Can. 2005, 12:19-47.
14. Vandeputte C., Guizon I., Genestie-Denis I., Vannier B., Lorenzon G. A microtiter plate assay for total glutathione and glutathione disulfide contents in cultured/isolated cells: performance study of a new miniaturized protocol. Cell Biol. Toxicol. 1994, 10:415-421.
15. Epsztejn S., Kakhlon O., Glickstein H., Breuer W., Cabantchik I. Fluorescence analysis of the labile iron pool of mammalian cells. Anal. Biochem. 1997, 248:31-40.
16. Wardman P. The importance of radiation chemistry to radiation and free radical biology (The 2008 Silvanus Thompson Memorial Lecture). Brit. J. Radiol. 2009, 82:89-104.
17. Estrela J.M., Ortega A., Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 2006, 43:143-181.
18. Esposito B.P., Epsztejn S., Breuer W., Cabantchik Z.I. A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal. Biochem. 2002, 304:1-18.
19. Gangloff M.B., Lai C., Van Campen D.R., Miller D.D., Norvell W.A., Glahn R.P. Ferrous iron uptake but not transfer is down-regulated in Caco-2 cells grown in high iron serum-free medium. J. Nutr. 1996, 126:3118-3127.
20. Gutteridge J.M. Ferrous-salt-promoted damage to deoxyribose and benzoate. The increased effectiveness of hydroxyl-radical scavengers in the presence of EDTA. Biochem. J. 1987, 243:709-714.